Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Longboard Pharmaceuticals, Inc. (symbol: LBPH) is a clinical-stage biopharmaceutical company dedicated to developing novel, transformative medicines aimed at treating rare neurological diseases. With a focus on optimized pharmacology and pharmacokinetics, Longboard's proprietary pipeline features multiple potentially first- or best-in-class programs that hold broad clinical utility.
The company is currently evaluating several promising drug candidates:
- LP352: A next-generation 5-HT2C agonist. This oral, centrally acting superagonist aims to treat developmental and epileptic encephalopathies (DEEs) while minimizing impact on 5-HT2B and 5-HT2A receptor subtypes.
- LP143: A centrally acting, full agonist of the cannabinoid type 2 receptor (CB2). This candidate is being developed for its potential therapeutic effects in neurological conditions.
- LP659: A highly selective, next-generation S1P receptor modulator with central action, being evaluated for its efficacy in treating neurological diseases.
Longboard Pharmaceuticals is driven by a team committed to delivering transformational medicines. The company’s focus on GPCR-targeted therapies aims to offer precise treatment options tailored to specific receptor subtypes, thereby enhancing efficacy and safety profiles. By advancing its clinical programs through rigorous scientific research and development, Longboard strives to address unmet medical needs and improve the quality of life for patients with rare neurological conditions.
Stay informed about the latest developments and updates from Longboard Pharmaceuticals, Inc. as they continue to make strides in the biopharmaceutical industry.
Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) has initiated an underwritten public offering to sell $20 million of its voting common stock. The company also anticipates granting the underwriters a 30-day option to purchase an additional $3 million of shares. The offering is made under a previously filed shelf registration statement, established on October 11, 2022, with a preliminary prospectus supplement to be filed with the SEC. No assurances are provided regarding the completion or terms of the offering.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced positive topline results from a Phase 1 clinical study of LP352, a 5-HT2C superagonist for neurological diseases. The study showed a strong correlation between plasma and cerebrospinal fluid (CSF) pharmacokinetics in a dose-dependent manner. LP352 also demonstrated early quantitative EEG changes, indicating receptor engagement, and favorable safety results consistent with previous studies. Longboard plans to provide further data on LP352’s potential as a treatment for seizures in developmental and epileptic encephalopathies.
Longboard Pharmaceuticals (NASDAQ: LBPH) announced the presentation of LP352, a selective 5-HT2C receptor superagonist, at the 2022 AES Annual Meeting. The data includes the effects of LP352 on prolactin and its binding activity at 5-HT2 receptors. The company is also hosting a scientific exhibit on the ongoing Phase 1b/2a PACIFIC Study, aimed at treating rare seizure disorders. The leadership team will be present to discuss LP352's potential as a best-in-class therapy for various developmental and epileptic encephalopathies.
Longboard Pharmaceuticals (Nasdaq: LBPH), a biopharmaceutical company, announced its participation in the Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day on November 15, 2022, in New York City. Senior leadership will engage in a fireside chat at 2:45 PM ET. A webcast will be available on their website for 30 days post-event. Longboard focuses on developing transformative medicines for neurological diseases, with key product candidates LP352, LP659, and LP143 under evaluation.
Longboard Pharmaceuticals (Nasdaq: LBPH) reported updates on its clinical studies and third-quarter financial results for 2022. The ongoing PACIFIC study for LP352, aimed at treating developmental and epileptic encephalopathies, is on track for topline data in the second half of 2023. The company has approximately $77.3 million in cash, which supports operations into 2024. R&D expenses rose to $9.4 million, primarily due to clinical trial costs, with a net loss of $11.6 million, or $0.68 per share, compared to a loss of $6.3 million, or $0.38 per share, in Q3 2021.
Longboard Pharmaceuticals (Nasdaq: LBPH) is participating in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022. Kevin Lind, President & CEO, will present on Next generation drugs, new targets and innovative approaches for high-unmet need epileptic disorders at 4:20 PM ET on October 6, 2022. This conference highlights innovations in treating neurological diseases, with Longboard showcasing its advancements in GPCR-targeted therapies for conditions like seizures and CNS disorders.
Longboard Pharmaceuticals (Nasdaq: LBPH) has announced participation in two significant upcoming conferences. The team will be at the Citi Annual BioPharma Conference on September 7-8, 2022, in Boston, and will also engage in a fireside chat at the H.C. Wainwright Global Investment Conference from September 12-14, 2022, in New York City. The H.C. Wainwright chat is scheduled for September 14 at 2:30 PM ET. Investors can access the presentations via Longboard's website, where they will also be archived for 30 days.
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) reported progress in its Phase 1b/2a PACIFIC Study of LP352, expected to complete in H2 2023. The study now includes participants aged 12-65 and has added an open-label extension. The company also initiated a Phase 1 study to assess CNS pharmacokinetics and pharmacodynamics of LP352. Additionally, an IND submission for LP659 is anticipated in Q4 2022. Financially, Longboard held approximately $87.4 million in cash at June 30, 2022, supporting operations into 2024. However, R&D expenses surged by 82% YoY, leading to a net loss of $11.4 million for Q2 2022.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced that Brandi Roberts, CFO, will participate in the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 12:35 PM ET. She will be a panelist in the session titled "Got My Mind Set On You - Advancing Novel Epilepsy Targets". Interested attendees can access the presentation via the Investors Relations section on Longboard’s website, with the presentation archived for 30 days post-event.
Longboard is focused on innovative therapies for neurological diseases, advancing products targeting specific GPCRs.
Longboard Pharmaceuticals (Nasdaq: LBPH) announced that Kevin Lind, the President & CEO, will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 3:00 PM ET in New York City. This clinical-stage biopharmaceutical company is focused on developing innovative medicines for neurological diseases. Interested parties can access a webcast of the presentation on Longboard’s website, where it will be archived for at least 30 days following the event.
FAQ
What is the current stock price of Longboard Pharmaceuticals (LBPH)?
What is the market cap of Longboard Pharmaceuticals (LBPH)?
What does Longboard Pharmaceuticals, Inc. specialize in?
What are the key drug candidates in Longboard's pipeline?
What is LP352?
What is unique about LP143?
What is the focus of Longboard Pharmaceuticals' research?
Who can benefit from Longboard's medicines?
How does Longboard ensure the safety of its treatments?
Is Longboard Pharmaceuticals a publicly traded company?
Where can I find the latest news about Longboard Pharmaceuticals?
What are the potential applications of LP659?
